AstraZeneca stock falls after Etcamah trial setback despite strong oncology pipeline
Published on 09/11/2026 at 23:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca PLC (ISIN GB0009895292) stock traded lower on September 11, 2026 after the company announced that its Etcamah breast cancer regimen failed to meet the primary endpoint in the SERENA-4 Phase III trial, even as broader earnings expectations and a strong oncology franchise continue to underpin investor interest.
Trial setback weighs on AstraZeneca shares
According to AstraZeneca on September 11, 2026, the SERENA-4 Phase III trial of Etcamah (camizestrant) in combination with the CDK 4/6 inhibitor palbociclib did not meet its primary endpoint of improving progression-free survival in first-line treatment for estrogen receptor-positive, HER2-negative advanced breast cancer, although a numerical improvement was observed in the upfront treatment setting.
As Reuters reported on September 11, 2026, AstraZeneca said its breast cancer drug failed to improve progression-free survival in the late-stage trial, highlighting the competitive and high-risk nature of oncology drug development.
The announcement noted that Etcamah in combination with a CDK 4/6 inhibitor is already approved in major markets including the US, EU and Japan for hormone receptor-positive, HER2-negative advanced breast cancer upon detection of ESR1 mutation based on earlier SERENA-6 data, so the SERENA-4 outcome represents a setback for expanding the label rather than a complete derailment of the medicine’s commercial trajectory.
Stock performance in London and on the NYSE
On its primary listing in London, AstraZeneca PLC shares recently traded around 11,870.00 pence on September 11, 2026 in intraday trading, compared with a previous close of 11,758.00 pence, implying a gain of about 0.95 percent on the day despite the trial disappointment, based on data from a London stock portal.
Market data from a London quote overview show that AstraZeneca stock closed at 11,758.00 pence on the London Stock Exchange on September 10, 2026, marking a 0.93 percent gain for that session, with the move valuing the group at roughly GBP 183.91 billion as of that close.
This price level on September 10, 2026 stands modestly above support indicated around 11,460.00 pence and below a technical resistance zone near 11,900.00 pence described in a technical commentary, pointing to a sideways trend with limited momentum ahead of fresh fundamental news.
On the US market, AstraZeneca’s American Depositary Shares (ticker AZN) closed at USD 159.71 on the New York Stock Exchange on September 10, 2026, up USD 2.77 or 1.76 percent on the day, according to data from a US stock analysis portal.
The same US portal indicates a consensus 12-month price target for AstraZeneca around USD 206.67 as of September 10, 2026, implying upside of roughly 29.4 percent from the USD 159.71 close, which frames investor expectations for medium-term returns despite near-term trial volatility.
Latest earnings context and expectations
According to Zacks as of September 11, 2026, the consensus estimate for AstraZeneca PLC’s earnings in the quarter ending in September 2026 stands at USD 2.17 per share, which the service expects the company to miss by 9.91 percent compared with its modelled outcome.
The same earnings overview notes that for the most recent reported quarter, AstraZeneca delivered earnings of USD 2.63 per share, beating the then current Zacks Consensus Estimate of USD 2.50 per share, corresponding to a positive earnings surprise of 5.20 percent; this outperformance provides a historical comparison point for investors assessing whether the expected decrease to USD 2.17 per share represents a temporary dip or a more structural slowdown.
Zacks also highlights that the forecast USD 2.17 per share for the September 2026 quarter would reflect a year-over-year decrease of 8.82 percent, suggesting that earnings growth may pause in the near term even as the company continues to invest heavily in its oncology pipeline and other therapeutic areas.
Based on past reporting patterns, the same source anticipates that AstraZeneca will publish its next quarterly earnings release on November 5, 2026, which market participants are likely to treat as a key checkpoint for validating whether the trial setbacks materially alter the earnings trajectory.
Analyst sentiment and oncology franchise
Beyond the SERENA-4 result, AstraZeneca’s broader oncology portfolio continues to generate supportive data. As Yahoo Finance reported on September 11, 2026, a combination of Amgen’s Imdelltra and AstraZeneca’s immunotherapy Imfinzi significantly improved overall survival in a late-stage trial in extensive-stage small-cell lung cancer compared with Imfinzi alone as maintenance therapy.
The lung cancer study also showed improvements in progression-free survival and response rates without new safety concerns, which the report describes as strengthening AstraZeneca’s long-term oncology franchise and potentially extending the commercial opportunity for Imfinzi, even though the immediate earnings impact is likely to be moderate.
This positive lung cancer data offers a counterweight to the disappointment around Etcamah in breast cancer, underscoring that the company’s oncology strategy is diversified across multiple indications and mechanisms, which may help mitigate stock volatility driven by any single trial outcome.
At the same time, some commentators remain cautious. A televised segment highlighted by Yahoo Finance on September 11, 2026 quoted Jim Cramer as saying he is nervous about AstraZeneca because of recent trial misses and does not intend to put his own money into the stock, arguing that chronic obstructive pulmonary disease opportunities alone are not sufficient to change his stance.
For investors, these mixed views illustrate the risk-reward balance: consensus price targets and positive trial data in lung cancer support the case for the shares, while failures such as SERENA-4 and high expectations embedded in the valuation highlight the need for continued execution across the pipeline.
Ownership trends and technical backdrop
AstraZeneca also remains a significant holding in institutional portfolios. A disclosure from JPMorgan Claverhouse Investment Trust dated September 11, 2026 listed AstraZeneca Group PLC as one of its ten largest investments, accounting for 4.5 percent of total assets as of August 31, 2026.
This sizeable weight in a UK income-focused investment trust signals that, despite individual trial disappointments, AstraZeneca continues to be viewed as a core defensive holding in the healthcare and pharmaceuticals segment, supported by its dividend and global scale.
Technical indicators around September 11, 2026 described momentum in the shares as subdued, with a relative strength index reading near 39.2 and price action in a sideways range between identified support and resistance levels, suggesting that traders are waiting for clearer fundamental catalysts before pushing the stock decisively higher or lower.
Stock price and key data
As of September 10, 2026, AstraZeneca’s American Depositary Shares closed at USD 159.71 on the New York Stock Exchange, up 1.76 percent on the day, with trading volume consistent with normal liquidity and a dividend yield cited around 2.72 percent by US market data providers.
Key data on AstraZeneca stock
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN
- Trading venue: New York Stock Exchange (ADR)
- Price (as of September 10, 2026): 159.71 USD
- Market capitalization: 247,690,000,000 GBP (as of September 10, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: FTSE 100
- Next earnings date: November 5, 2026
